Trastuzumab trials for HER2-positive Breast Cancer

All Trastuzumab trials · All HER2-positive Breast Cancer trials

Phase breakdown

Recruiting trials studying Trastuzumab for HER2-positive Breast Cancer

• A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
  NCT07102381 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 35 locations
• A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
  NCT07518173 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: Female · 2 locations
• A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
  NCT06891833 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: Female · 30 locations
• BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer
  NCT06441890 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer
  NCT04993014 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
  NCT05582499 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
  NCT07377643 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Pre Operative Trastuzumab in Operable Breast Cancer
  NCT01785420 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: Female · 1 location
• RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
  NCT07413939 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 186 locations
• Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
  NCT05325632 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
  NCT06217185 · Phase: Phase 4 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
  NCT04886531 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study
  NCT06016387 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations

Common questions

How many trials study Trastuzumab for HER2-positive Breast Cancer?

13 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.